CancerDrs Find care

Sarcoma clinical trials in North Dakota

10 actively recruiting sarcoma trials at 5 sites across North Dakota.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in North Dakota:
  • Sanford Bismarck Medical Center — Bismarck, North Dakota
  • Sanford Broadway Medical Center — Fargo, North Dakota
  • Sanford Roger Maris Cancer Center — Fargo, North Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in North Dakota:
  • Sanford Broadway Medical Center — Fargo, North Dakota
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in North Dakota:
  • Sanford Broadway Medical Center — Fargo, North Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…

Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in North Dakota:
  • Sanford Broadway Medical Center — Fargo, North Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in North Dakota:
  • Sanford Bismarck Medical Center — Bismarck, North Dakota
  • Sanford Broadway Medical Center — Fargo, North Dakota
  • Sanford Roger Maris Cancer Center — Fargo, North Dakota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in North Dakota:
  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003) — Fargo, North Dakota
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this st…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07252739
Sites in North Dakota:
  • Sanford Health Roger Maris Cancer Center ( Site 0039) — Fargo, North Dakota
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (adv…

Sponsor: Mayo Clinic
NCT ID: NCT05969860
Sites in North Dakota:
  • Altru Cancer Center — Grand Forks, North Dakota
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in North Dakota:
  • Sanford Bismarck Medical Center — Bismarck, North Dakota
  • Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
  • Sanford South University Medical Center — Fargo, North Dakota
  • Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
  • Sanford Medical Center Fargo — Fargo, North Dakota
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in North Dakota:
  • Essentia Health — Fargo, North Dakota
  • Trinity Hospital Cancer Care Center — Minot, North Dakota
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20